Delivery Order SPE2DB25D3108-SPE2DB25FPDJR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,948.40 to AmerisourceBergen Drug Corp for Xulane 150-35 mcg/day transdermal patches (3-count package), effective August 26, 2025, with completion targeted for August 27, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performs under this delivery order at its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $2,868.75 to AmerisourceBergen Drug Corp for Xulane 150-35 mcg/day contraceptive patches (3-pack unit) on September 29, 2025, with completion scheduled for September 30, 2025. The contract utilized firm fixed price pricing with no set-aside designation, indicating competitive award through open competition. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,610.48 to AmerisourceBergen Drug Corp for Xulane 150-35 mcg/day transdermal patches (3-unit supply) on June 20, 2025, with an ultimate completion date of June 23, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xulane 150-35 mcg/day contraceptive patches (3-unit package) with a ceiling value of $2,137.02. This non-competitive delivery order, awarded on September 3, 2025, represents a firm fixed-price transaction with an ultimate completion date of September 4, 2025. The contractor will fulfill this order from its facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $1,428.13 to AmerisourceBergen Drug Corp for Xulane 150-35 mcg/day contraceptive patches (3-pack units). This competitively awarded, non-set-aside delivery order reflects firm fixed pricing and is scheduled for completion by July 29, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform fulfillment from its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for $4,418.88 to supply Xulane 150-35 mcg/day transdermal patches (quantity: 3 units). This is a firm fixed price delivery order with no set-aside designation, completed competitively under the company's larger indefinite delivery contract with DLA Troop Support Medical. The order is set to be fulfilled by the ultimate completion date of August 13, 2025, with the place of performance in...
- The Defense Logistics Agency awarded a delivery order valued at $3,860.10 to AmerisourceBergen Drug Corp for Xulane 150-35 mcg/day contraceptive patches (3-count). This firm fixed price, non-competitive delivery order was issued on September 24, 2025, with an ultimate completion date of September 25, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $1,015.60 to AmerisourceBergen Drug Corp for Xulane 150-35 mcg/day transdermal patches (3-count package). The contract, issued on April 21, 2025, with an ultimate completion date of April 22, 2025, represents a firm fixed-price delivery order with no set-aside designation. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract executed...
- The Defense Logistics Agency awarded a $2,206.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Xulane 150-35 mcg/day contraceptive patches (3-count supply) on August 21, 2025, with completion scheduled for August 22, 2025. This non-competitive delivery order was issued from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $2,018.96 to AmerisourceBergen Drug Corp for Xulane 150-35 mcg/day contraceptive patches (3-count packages). This firm fixed-price delivery order, issued on June 5, 2025, with a completion date of June 6, 2025, was competitively awarded without set-aside designation. The pharmaceutical product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- SPE2DB25D3108Indefinite Delivery Contract
- SPE2DB25D3108-SPE2DB25FPDJRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,945.86 to AmerisourceBergen Drug Corp for Xulane 150-35 mcg/day patches (3-count units), with an ultimate completion date of July 21, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its Corporate Office location. This award represents a single transaction under the company's broader federal contract portfolio focused on pharmaceutical and medical supply distribution to military and federal healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. As a prime pharmaceutical vendor supporting the Defense Logistics Agency's medical supply chain, AmerisourceBergen maintains an extensive portfolio of federal contracts encompassing brand-name and generic pharmaceuticals, vaccines, medical devices, and specialized healthcare commodities serving defense and veteran healthcare systems worldwide. The company's competitively awarded contracts with DLA demonstrate its established capability to fulfill federal medical procurement requirements across multiple therapeutic domains on a global scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 7/18/25 |